Lenalidomide-based triplet regimens in first relapsed multiple myeloma patients: real-world evidence from a propensity score matched analysis

Lenalidomide and dexamethasone (Rd)-based triplets, in particular carfilzomib-Rd (KRd) and daratumumab-Rd (DaraRd), represent a standard of care in lenalidomide-sensitive multiple myeloma (MM) patients in first relapse. Meta-analysis of randomized clinical trials (RCT), suggested better outcome with...

Descripción completa

Detalles Bibliográficos
Autores principales: Mangiacavalli, Silvia, Cartia, Claudio Salvatore, Galli, Monica, Pezzatti, Sara, Belotti, Angelo, Fazio, Francesca, Mina, Roberto, Marcatti, Magda, Cafro, Anna, Zambello, Renato, Paris, Laura, Barilà, Gregorio, Olivares, Cecilia, Pompa, Alessandra, Mazza, Rita, Farina, Francesca, Soldarini, Martina, Benvenuti, Pietro, Pagani, Giuseppina, Palumbo, Michele, Masoni, Valeria, Ferretti, Virginia Valeria, Klersy, Catherine, Arcaini1, Luca, Petrucci, Maria Teresa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2022
Materias:
Article - Plasma Cell Disorders
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9973473/
https://www.ncbi.nlm.nih.gov/pubmed/36200419
http://dx.doi.org/10.3324/haematol.2022.281342

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9973473/
https://www.ncbi.nlm.nih.gov/pubmed/36200419
http://dx.doi.org/10.3324/haematol.2022.281342

Ejemplares similares